Fine epitope mapping of monoclonal antibodies to the NH2‐terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain
- 1 May 1994
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 87 (1) , 113-118
- https://doi.org/10.1111/j.1365-2141.1994.tb04879.x
Abstract
Summary: . Two different approaches were used in order to define the epitope of three monoclonal antibodies (MoAbs) against the NH2‐terminal part of the mature subunit of von Willebrand factor (vWF) which contains its factor VIII (FVIII) binding site. First, a vWF cDNA fragment library using the bacteriophage λgt11 expression vector was screened with radiolabelled MoAbs. The epitope of each MoAb was defined, following sequence analysis, by the overlapping DNA sequence of immunoreactive clones. MoAb 32B12, a potent inhibitor of FVIII/vWF interaction, binds within the Glu35‐Ile81 sequence of vWF subunit. MoAb 14A12, a non‐inhibitory antibody, recognizes a sequence within Thr141‐Val220. MoAb 31H3, a partial inhibitory antibody, gives no positive clone. In the second method, a panel of 24 synthetic pentadecapeptides corresponding to the first NH2‐terminal 105 amino acid residues was used to block the binding of inhibitor MoAbs to immobilized vWF in an ELISA system. The localization of MoAb 32B12 epitope was confirmed and restricted to the Met51‐Ala60 sequence, The MoAb 31H3 binding to vWF is inhibited by two synthetic peptides with the overlapping sequence Cys66‐Gly76. All these data confirm that the FVIII binding site of vWF is not limited to the binding area (Thr78‐Thr96) of the previously described MoAbs inhibiting FVIII/vWF interaction but is composed of several key sequences.Keywords
This publication has 34 references indexed in Scilit:
- A patient with von Willebrand's disease characterized by a compound heterozygosity for a substitution of Arg by Gln in the putative factor‐VIII‐binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF alleleBritish Journal of Haematology, 1992
- Identification of two point mutations in the von Willebrand factor gene of three families with the ‘Normandy’variant of von Willebrand diseaseBritish Journal of Haematology, 1991
- Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counsellingBritish Journal of Haematology, 1990
- Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNAGenomics, 1990
- Localization within the 106 N-terminal amino acids of von Willebrand Factor (vWF) of the epitope corresponding to a monoclonal antibody which inhibits vWF binding to factor VIIIBiochemical and Biophysical Research Communications, 1989
- A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.Journal of Clinical Investigation, 1989
- Amino acid sequence of human von Willebrand factorBiochemistry, 1986
- Hybridoma antibodies to human von Willebrand factorBritish Journal of Haematology, 1984
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978
- Stabilization of Factor VIII in Plasma by the von Willebrand FactorJournal of Clinical Investigation, 1977